Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
SAN DIEGO, May 14 /PRNewswire-AsiaNet/ --
Collaboration will leverage HUYA's growing Chinese bioscience
network
HUYA Bioscience International, a leader in US/China pharmaceutical
co-development, today announced an agreement with Abbott to identify and
pursue proprietary preclinical and clinical drug candidates that originate in
China.
Abbott will gain access to HUYA's growing Chinese bioscience network
comprising premier companies, universities, government research institutions
and bioparks throughout the country. HUYA has agreements in place with many
of these organizations whereby HUYA has ongoing exclusive access to compounds
and biologics in a variety of indications. HUYA is currently evaluating and
following the progress of more than 600 lead, preclinical and clinical drug
candidates.
"China has an extremely rich pool of drug candidates, which we are able
to tap through our extensive network of partners," said Mireille Gingras,
PhD, President and CEO of HUYA. "We've been effective in leveraging those
relationships to the mutual benefit of our partners in the West and in China,
and we're looking forward to a productive collaboration with Abbott."
HUYA's model is based on long-term relationships with its Chinese
partners and this provides a continuous source of compounds, unlike a single
compound strategy. Once a compound is licensed, the ongoing exchange of
expertise and data lowers risk and facilitates rapid and efficient clinical
development in both China and the West.
HUYA currently has two clinical stage drugs licensed from China in the
therapeutic areas of Cardiovascular and Oncology for development in the West.
HUYA's innovative model benefits partners in the West and China
HUYA was one of the first companies to recognize China's potential to
help meet the global need for pre-clinical and clinical stage compounds for
the drug development process. HUYA identifies and licenses highly promising
pre-clinical and clinical stage compounds in China and provides access to
those compounds to partners in the West. Likewise, HUYA provides a valuable
bridge to Western development for its partners in China. HUYA's Chinese
partners retain development and marketing rights in China with the
expectation that both parties will benefit from the research and development
collaboration.
One of the key differentiators of HUYA's approach is the assembly of a
high-level team of scientific and clinical advisors for each new compound.
The team collaborates with its Chinese partners to discuss and design
pre-clinical tests and clinical trials as the compounds enter the U.S.
development process, speeding the process and mitigating risk. HUYA's global
team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD,
Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel,
MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and
Michael Robertson, MD.
"HUYA has forged highly productive relationships with its Chinese
partners, which sets up the potential for clinical development and new
treatment options in several diseases," said Eric Topol, Chief Academic
Officer, Scripps Health, San Diego, CA.
About HUYA
HUYA is a leader in U.S./China pharmaceutical co-development with four
strategic offices in China, a broad Chinese compound portfolio, and a
significant number of exclusive agreements with premier Chinese biotech
centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai.
USA: China:
Jan Tuttleman, PhD Li Zhu, PhD
Vice President, Marketing VP China Operations
HUYA Bioscience International, LLC HUYA Bioscience International, LLC (858) 798-8800 86
(21) 51323312
jtuttleman@huyabio.com lzhu@huyabio.com
Media Contact:
Juliet Travis
(510) 452-3771
juliet@travispr.com
SOURCE: HUYA Bioscience International
CONTACT: USA,
Jan Tuttleman, PhD, Vice President, Marketing,
+1-858-798-8800,
jtuttleman@huyabio.com, or
China,
Li Zhu, PhD, VP China Operations,
86 (21) 51323312,
lzhu@huyabio.com, both of HUYA Bioscience International; or
Media,
Juliet Travis,
+1-510-452-3771,
juliet@travispr.com, for HUYA Bioscience International
NEWS 
